Journal of Undergraduate Research


interleukin-1 beta, methamphetames, dopamine release, mesolimbic pathway


Family, Home, and Social Sciences




In this study we wanted to determine the effect that Interleukin-1 Beta (IL-1𝛃) would have in changing the effects that methamphetamines have on dopamine release in the nucleus accumbens (reward center of the brain). It has been well established previously that methamphetamines increases dopamine levels in the nucleus accumbens. Given that IL-1𝛃 increases inflammation in the brain which has been seen to be involved in dopamine release and that IL-1𝛃 is able to act on other parts of the brain, we suspected that by inhibiting IL-1𝛃 we would see a decrease in dopamine response to methamphetamines. If the IL-1𝛃 blocker, Kineret, were able to inhibit the meth-induced dopamine spike, it would be a potential candidate as a drug that could reverse addiction pharmacologically.